---
document_datetime: 2023-09-21 17:44:48
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/benefix-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: benefix-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 0.6972963
conversion_datetime: 2025-12-30 12:07:45.516728
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Procedural steps taken after granting the Marketing Authorisation

## For procedures finalised after 1 September 2000 please refer to module 8B.

- The Marketing Authorisation Holder (MAH), in accordance with Commission Regulation (EC) No.  542/95  submitted  an  application  for  a  Type  I  variation  to  change  the  name  of  the manufacturer  of  the  finished  medicinal  product  from  Sanofi  Winthrop,  Inc.,  USA  to  Abbott Laboratories, USA. The variation was accepted on 22 April 1998.
- The  MAH,  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  submitted  an application for a Type II variation which referred to the optimisation of the lyophilisation cycle, which was withdrawn on 8 July 1998.
- The MAH in accordance with Commission Regulation (EC) No. 542/95, as amended, submitted an application for a Type II variation to amend the text of the SPC, labelling and Package Leaflet in the light of the data in the first PSUR. The proposed texts included revised information on posology, pharmacokinetics and adverse reactions, including cases of severe anaphylaxis. A positive opinion was adopted by the CPMP on 23 July 1998. The Commission decision amending the marketing authorisation was adopted on 11 November 1998.
- The MAH in accordance with Commission Regulation (EC) No. 542/95, as amended, submitted an  application  for  a  Type  I  variation  which  referred  to  a  change  in  the  specification  of  the medicinal product; a notification was issued on 8 December 1998.
- The MAH in accordance with Commission Regulation (EC) No. 542/95, as amended, submitted an  application  for  a  Type  I  variation  which  referred  to  a  change  in  the  specification  of  the medicinal product; a notification was issued on 8 December 1998.
- The MAH in accordance with Commission Regulation (EC) No. 542/95, as amended, submitted an application for a Type I variation which referred to a change in the specification of the active substance; a notification was issued on 8 December 1998.
- The MAH in accordance with Commission Regulation (EC) No. 542/95, as amended, submitted an application for a Type I variation which referred to a change in the specification of the active substance; a notification was issued on 9 October 1998.
- The MAH in accordance with Commission Regulation (EC) No. 542/95, as amended, submitted an application for a Type I variation which referred to a change in the address of the Marketing Authorisation Holder; and a notification was issued on 26 October 1998.  The Commission Decision amending the Marketing Authorisation was adopted on 11 January 1999.
- Persuant to Article 13(2) of Council regulation (EC) No. 2309/93, as amended, the Marketing Authorisation  Holder  submitted  to  the  EMEA  on  27  August  1998,  the  documentation  that formed  the  basis  of  the  first  annual  re-assessment  of  the  benefit/risk  profile  for  BeneFIX.  A positive  opinion  was  issued  on  19  November  1998.  The  Commission  Decision  amending  the Marketing Authorisation was adopted on 29 March 1999.
- Pursuant  to  Article  10(3)  of  Council  Directive  No.  92/27/EEC,  the  Marketing  Authorisation Holder notified the EMEA of a change of address of the Greek representative; a notification was issued on 22 February 1999. The Commission Decision amending the Marketing Authorisation was adopted on 8 April 1999.
- The MAH in accordance with Commission Regulation (EC) No. 542/95, as amended, submitted an application for a Type I variation which referred to a change in the specification of the active substance; a notification was issued on 30 June 1999.
- The MAH in accordance with Commission Regulation (EC) No. 542/95, as amended, submitted an application for a Type I variation which referred to a change in specification of the finished product; a notification was issued on 30 June 1999.
- Persuant to Article 13(2) of Council regulation (EC) No. 2309/93, as amended, the Marketing Authorisation  Holder  submitted  to  the  EMEA  on  2  September  1999,  the  documentation  that

<div style=\"page-break-after: always\"></div>

formed the basis of the second annual re-assessment of the benefix/risk profile for BeneFIX. A positive  opinion  was  issued  on  18  November  1999.  The  Commission  Decision  amending  the Marketing Authorisation was adopted in March 2000.